+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer



Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer



Oncology Letters 10(4): 2598-2602



The present study aimed to analyze the efficacy of maintenance therapy with single agent capecitabine for human epidermal growth factor receptor (HER2) negative metastatic breast cancer (MBC) patients following disease control with 6 cycles of docetaxel plus capecitabine chemotherapy as the first-line treatment. As an initial treatment, 6 cycles of docetaxel plus capecitabine followed by maintenance therapy with capecitabine were administered. A total of 55 patients received combination therapy and 48 patients proceeded to maintenance therapy: Of these, 32 patients (66.7%) were postmenopausal and 37 (77.1%) had estrogen and progesterone receptor positive disease. The median progression-free survival rate with maintenance therapy was 5.5 months (95% CI, 0-11.4 months) and the median overall survival (OS) was 26.6 months (95% CI, 21.8-30.1 months). The use of maintenance therapy improved previous responses in 4 patients (8.3%; 2 partial and 2 complete responses) and 32 patients (66.7%) had stable disease. The median number of maintenance therapy cycles applied was 6.5 (range 1-28, total 441). The observation of side effects, including grade 3/4 neutropenia, febrile neutropenia and fatigue was more common during combination therapy. The results of the present study indicate that maintenance with single agent capecitabine therapy is an effective and tolerable treatment option for HER2 negative MBC patients in which disease control with 6 cycles of docetaxel plus capecitabine chemotherapy is achieved in the first-line setting.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057352117

Download citation: RISBibTeXText

PMID: 26622896

DOI: 10.3892/ol.2015.3546


Related references

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncology Letters 9(2): 987-993, 2015

Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer. Chinese Journal of Cancer 35: 39, 2016

Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. Anti-Cancer Drugs 23(7): 718-723, 2012

Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer. Chinese Journal of Cancer Research 26(6): 692-697, 2015

Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial. Cancer 121(19): 3412-3421, 2016

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer. Cancer ChemoTherapy and Pharmacology 71(4): 1051-1057, 2013

Survival update of so14999 a large phase III trial of capecitabine/docetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced or metastatic breast cancer. European Journal of Cancer 37(Suppl. 6): S151, 2001

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. Journal of Clinical Oncology 31(23): 2870-2878, 2013

The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer. International Journal of Clinical and Experimental Medicine 8(5): 8283-8287, 2015

Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). Journal of Clinical Oncology 24(18_Suppl): 571-571, 2016

A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Breast Journal 19(3): 240-249, 2013

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. Journal of Oncology 2012: 862921, 2012

Capecitabine and docetaxel in the treatment of metastatic breast cancer combination, sequence or single agent?. EJC Suppl.s 6(8): 5-8, 2008

Population based cost-effectiveness analysis of combination capecitabine and docetaxel versus single agent docetaxel in the treatment of metastatic breast cancer following an anthracycline regimen. European Journal of Cancer 38(Suppl. 3): S67, 2002

Optimize administration protocol of capecitabine plus docetaxel combination in metastatic breast cancer patients. Current Topics in Medicinal Chemistry 12(15): 1665-1668, 2013